Inhibitory antibodies in hemophilia A
KP Pratt - Current opinion in hematology, 2012 - journals.lww.com
Current opinion in hematology, 2012•journals.lww.com
Studies of FVIII immunogenicity are revealing mechanisms of anti-FVIII immune responses,
suggesting new approaches to reduce the incidence of inhibitors. Rational design of FVIII
variants is producing less immunogenic proteins targeted to specific patient sub-
populations. Future therapies will likely involve administration of less immunogenic FVIII
proteins under conditions that promote immune tolerance.
suggesting new approaches to reduce the incidence of inhibitors. Rational design of FVIII
variants is producing less immunogenic proteins targeted to specific patient sub-
populations. Future therapies will likely involve administration of less immunogenic FVIII
proteins under conditions that promote immune tolerance.
Summary
Studies of FVIII immunogenicity are revealing mechanisms of anti-FVIII immune responses, suggesting new approaches to reduce the incidence of inhibitors. Rational design of FVIII variants is producing less immunogenic proteins targeted to specific patient sub-populations. Future therapies will likely involve administration of less immunogenic FVIII proteins under conditions that promote immune tolerance.
Lippincott Williams & Wilkins